Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
The companies plan to start a pivotal Phase 3 trial in the coming months
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Apollo's unparalleled clinical excellence is built on extensive experience of performing over 300,000 angioplasties and 200,000 cardiac surgeries
Capital raise to accelerate product and technology development and support expansion efforts to reshape communications to HCPs across the globe
Kivo’s expanded platform brings compliant collaboration and intelligent process automation to emerging Regulatory, Clinical and Quality teams
Commenced operations in flood-affected Himachal Pradesh
Reinforces Henkel commitment to supporting customers and ecosystem in medical healthcare
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
Subscribe To Our Newsletter & Stay Updated
